Biotech Investment Barometer Reveals Continued Confidence in Sector
* Early-stage funding environment eases slightly in Europe
* Improved relationship between big pharma and biotech
Munich/Zug, 2 October 2007 - Global Life Science Ventures (GLSV)
today released the results of its 3rd Annual GLSV Biotech Investment
Barometer. The survey of the biotech and investment communities
revealed that the sector continues to be viewed positively by a large
majority of participants, although the level of optimism is slightly
lower compared with last year. The results are being presented at
Sachs Associates' Biotech in Europe Investment Forum, held in Zurich
on 2-3 October 2007.
Among the 200 respondents to the survey, carried out in
mid-September, 79% were based in Europe, with the remainder mainly in
North America. Biotech executives and members of the investment
community represented 40% and 50% of participants, respectively. The
following are key results and conclusions from the survey.
Continued positive outlook
The overall outlook for the biotech sector remains clearly
optimistic, though somewhat less so than last year. 68% of European
respondents see the future of the European biotech sector as fairly
or highly positive, down from 75% in 2006. 19% see it as negative, an
increase from 9% in 2006. The 42% of European respondents who say
they are more optimistic than 12 months ago is down from the 59% who
gave the same response in 2006, with 29% now more pessimistic.
Impact of recent clinical results and drug approvals
A factor in the tempered optimism is recent clinical results and drug
approvals, which are seen by 34% of European participants as having a
negative impact on market sentiment, whereas only 20% see a positive
impact.
Improved relationship between big pharma and biotech
The symbiotic relationship between pharma and biotech is of great
importance to the biotech sector, and big pharma's attitude toward
biotech companies is considered by 80% of European respondents to
have improved in recent years. 69% also consider that big pharma has
made more effective use of biotech's innovations to fill its
pipelines in recent years.
Slight improvement in early-stage funding environment
There is a positive shift in the perception of the funding
environment for early-stage biotech companies in Europe. While still
viewed as difficult or very difficult by 62% of European respondents,
this number is down from 74% last year, while fully 23% view it as
good or excellent, up from 13% last year.
The US funding environment is again considered good or excellent by
45% of European respondents (42% last year), while only 18% consider
it difficult or very difficult. North American respondents were,
however, much more likely to view their own funding environment as
difficult.
IPO market conditions similar in Europe and US
Europe and the US are now considered to have similar market
conditions for IPOs, with respondents split approximately equally
among those saying the conditions are still more favourable in
Europe, about the same, and less favourable in Europe.
The two most important factors for the success of an IPO were
considered to be a late stage product and a strong management team.
Investors tended to place at least as great importance on the
strength of the management team (34% ranked first) as a product in
Phase III (28% ranked first). On the other hand, 50% of biotech
executives viewed a product in Phase III as the most important
factor, with only 15% viewing the strength of the management team as
the number one factor. The number of products in the pipeline came
third in the ranking, followed closely by the size of the therapeutic
market.
Biotech stocks considered undervalued; good performance expected
European biotech stocks are still considered to be undervalued by 63%
of European respondents (68% in 2006), despite performing well in the
past year. Biotech executives are more likely by a 10% margin to
consider them undervalued than the investment community. North
American respondents were, on the other hand, more likely to view
European biotech stocks as overvalued (42%).
There is a greater tendency since last year to view US biotech stocks
as undervalued (34% vs 29% last year among European respondents),
with fewer viewing the stocks as overvalued (21% vs 29% last year).
49% of European respondents expect biotech shares to outperform the
stock market in the next 12 months, while only 22% expect them to
underperform. Biotech executives and investors had similar views.
Mixed views on attractiveness of US vs Europe
Respondents were split between 48% who view the US as a more
attractive region for life science VCs and 48% who consider the US
and Europe equally attractive or Europe more attractive. The
investment community was more likely than biotech executives to
consider Europe as more attractive than the US (18% vs 7%).
Dr. Peter Reinisch, Partner at GLSV, commented, "The results show
that the European biotech sector is maturing and continues to be
viewed positively by a large majority of respondents, despite some
difficulties with clinical trials and drug approvals. With all the
fundamentals in place, the sector will continue to grow and fulfill
its expectations as the source of innovative new drugs for the pharma
industry's pipeline."
The full presentation with the Barometer results is available on the
GLSV website at www.glsv-vc.com in the section "Download Area".
About Global Life Science Ventures
GLSV is a leading, independent venture capital fund focusing
exclusively on the life sciences. With offices in Switzerland and
Germany, GLSV is dedicated to supporting early-stage companies
originating from universities, scientific institutions or industry,
but also invests in selected later-stage companies, including
buy-outs. The group currently advises and manages funds totaling more
than ¤200 million. GLSV has now financed 34 innovative life science
companies throughout Europe and the USA, thirteen of which have
completed an exit through IPO, trade sale or M&A. Since 1996, GLSV
has built up a broadly diversified portfolio of companies in
pharmaceuticals, diagnostics, medical devices, and biotechnology.
Global Life Science Ventures
Industry-born team - Proven track record - Global perspective
Germany Switzerland
GLSV GmbH GLSV
AG
Von-der-Tann-Str. 3 Postplatz
1, P.O. 626
D - 80539 München CH - 6301
Zug
Tel. +49 (0)89 288 151 0 Tel. +41
(0)41 727 19 40
Fax +49 (0)89 288 151 30 Fax +41 (0)41
727 19 45
www.glsv-vc.com
mailbox@glsv-vc.com
For additional information, please contact:
Rochat & Partners MC Services
(Germany)
Jonathan Leighton or Christophe Lamps Stefan Riedel
Tel. +41 22 786 54 55 Tel. +49
(0) 89 210 228 40
Fax +41 22 786 54 58 Fax +49 (0)
89 210 228 88
E-mail: jleighton@rochat-pr.ch E-mail:
stefan.riedel@mc-services.eu
clamps@rochat-pr.ch